Concepedia

Lead Compound Prioritization

Lead Compound Prioritization is a computational or analytical method within structure-activity relationship analysis that ranks candidate compounds based on their predicted biological activity, physicochemical properties, and potential for optimization to identify the most promising candidates for further drug development.

122

Publications

5.3K

Citations

806

Authors

202

Institutions

Publications per year

2017–2026

35

Parents

Publications

122

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

Arup K. Ghose, Torsten Herbertz, Robert L. Hudkins et al. · ACS Chemical Neuroscience · 2011 · 437 citations · Full text

, , +17

Molecular obesity, potency and other addictions in drug discovery

Michael M. Hann · MedChemComm · 2011 · 354 citations

, , +17

Topomer CoMFA:  A Design Methodology for Rapid Lead Optimization

Richard D. Cramer · Journal of Medicinal Chemistry · 2003 · 198 citations

, , +17

Current trends in lead discovery: Are we looking for the appropriate properties?

Tudor I. Oprea · Journal of Computer-Aided Molecular Design · 2002 · 193 citations

, , +15

Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans

Vivek C. Abraham, Danli L. Towne, Jeffrey F. Waring et al. · SLAS DISCOVERY · 2008 · 148 citations · Full text

, , +17

1–5 of 122

Authors

806

  1. AB
    Andrew Baxter

    British American Tobacco (United Kingdom), United Kingdom

    4 publications · 311 citations

    4

    h-index

  2. JU
    John Unitt

    Loughborough University, United Kingdom

    3 publications · 191 citations

    3

    h-index

  3. SB
    Steve Brough

    Loughborough University, United Kingdom

    3 publications · 257 citations

    3

    h-index

  4. TM
    Tom McInally

    Loughborough University, United Kingdom

    3 publications · 257 citations

    3

    h-index

  5. AC
    Anne Cooper

    AstraZeneca (United Kingdom), United Kingdom

    3 publications · 191 citations

    3

    h-index

1–5 of 806

Institutions

202

  1. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    7 h-index

    63 publications

    4.1K citations

  2. Loughborough University

    Loughborough, United Kingdom

    6 h-index

    55 publications

    3.5K citations

  3. AstraZeneca (Sweden)

    Södertälje, Sweden

    5 h-index

    20 publications

    408 citations

  4. Abbott (United States)

    Chicago, United States

    3 h-index

    23 publications

    526 citations

  5. Pfizer (United Kingdom)

    Tadworth, United Kingdom

    3 h-index

    10 publications

    168 citations

  6. University College London

    London, United Kingdom

    3 h-index

    6 publications

    124 citations

  7. Sichuan University

    Chengdu, China

    3 h-index

    27 publications

    763 citations

  8. Novartis (Switzerland)

    Basel, Switzerland

    3 h-index

    8 publications

    220 citations

1–8 of 202

Venues

  1. Bioorganic & Medicinal Chemistry Letters

    19 publications · 585 citations

    15

    h-index

  2. Journal of Medicinal Chemistry

    13 publications · 738 citations

    13

    h-index

  3. European Journal of Medicinal Chemistry

    9 publications · 280 citations

    9

    h-index

  4. Journal of Chemical Information and Modeling

    JCIM · 4 publications · 183 citations

    4

    h-index

  5. PLoS ONE

    4 publications · 177 citations

    4

    h-index

1–5